MedTrace Logo

Study of ONO-2506 in Patients With Acute Ischemic Stroke

NCT00229177 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 757

Last updated 2012-06-13

No results posted yet for this study

Summary

The purpose of this study is to determine the efficacy and safety of ONO-2506 compared to placebo in patients with acute ischemic stroke.

Conditions

Interventions

DRUG

ONO-2506

Once daily one-hour intravenous infusion at 12/mg/kg/hr for 7 days

DRUG

ONO-2506

Once daily one-hour intravenous infusion at 0 mg/kg/hr for 7 days

DRUG

ONO-2506

Once daily one-hour intravenous infusion at 8 mg/kg/hr for 7 days

Sponsors & Collaborators

  • Ono Pharmaceutical Co. Ltd

    lead INDUSTRY

Principal Investigators

  • Project Leader, Development Planning · Ono Pharmaceutical Co. Ltd

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-09-30
Primary Completion
2008-09-30
Completion
2008-09-30

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00229177 on ClinicalTrials.gov